MET and neoplasm: This group had nearly 1.0 CRGA/tumor with a variety of potential molecular targets including KIT, MET, FGFR1, and TSC2 (Fig. 2D); only one case out of the 30 cases harbored a TP53-mutant/RB1-mutant profile.